SAN DIEGO, Nov. 27 /PRNewswire-FirstCall/ -- Bridgetech Holdings International, Inc., and The Chinese University of Hong Kong recently celebrated the grand opening of the new facilities for their contract research organization (CRO) -- Bridgetech Medical Technologies Research & Development Limited (BMT).
BMT is a world class CRO established to manage clinical trials and to facilitate regulatory approval from China’s State Food and Drug Administration (SFDA) and the U.S. Food and Drug Administration (FDA).
Mr. Michael Chermak, Chairman and CEO of Bridgetech, said at the opening ceremony, “BMT is a vital component of our business strategy underlining our ability to manage effectively the regulatory process as a pre-requisite to the introduction of the world’s best science to China.”
He continued, “There is a higher and much more important purpose for BMT. It advances research and development of life saving medical technology to the people of China and beyond.”
Also at the ceremony, Professor Kenneth Young, Pro-Vice-Chancellor, CUHK, said that CUHK values this partnership. CUHK shares Bridgetech’s vision and sees a lot of synergy between the two organizations.
The Centre for Clinical Trials (CCT) at CUHK is the only trial site outside Mainland China which has been approved by the SFDA for conducting oncology trials.
Professor Young said, “Hong Kong plays a strategically important role in the healthcare development in Greater China. The collaboration presents a good opportunity for both organizations.” He looked forward to having this relationship as one further step towards more academic collaboration between the University and the US life science community.
Located at the Hong Kong Science & Technology Parks, BMT is the first CRO headquartered in Hong Kong, also serving Greater China. The CRO will be able to perform clinical trial services in which the data will be acceptable to both the SFDA and FDA. BMT will also provide other companies with clinical trials and other regulatory services.
Mr. Carlos Genardini, CEO, Hong Kong Science & Technology Parks Corporation, was happy to welcome in BMT. He said, “Biotech represents a tremendous opportunity for medicine. We are delighted that Bridgetech Medical Technologies has recognized the benefits of Hong Kong in this area. Based at the Hong Kong Science Park, BMT will be able to leverage Hong Kong’s excellent clinical research infrastructure, our strategic location for access to the Mainland China market, robust intellectual property protection, and not least the excellent facilities and R&D environment here at the Hong Kong Science Park.”
“By supporting innovative companies such as BMT, we hope to be a catalyst for their further success. As our biotech cluster develops further, I’m confident about our ability to build a vibrant industry for Hong Kong.”
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and the U.S. to capitalize on the demand for Western healthcare in China. The company is bringing emerging drugs, devices and diagnostics to China, with an initial focus on oncology and women’s health. Bridgetech has also established domestic operations to support its China initiatives. For additional information, please visit www.bthi.com.
Forward-Looking Statements.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning expectations, beliefs, goals, intention or strategies for the future of Bridgetech. Forward-looking statements may be identified by words such as “goals,” “plans,” “believes,” “will,” “expects” and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. Investors are cautioned not to place any undue reliance on any forward-looking statements.
Contacts: Media Relations: Vince Heald, Beck Ellman Heald - 858-453-9600 vheald@behmedia.com Investor Relations: Redwood Consultants, LLC - 415-884-0348
Bridgetech Holdings International, Inc.
CONTACT: Media Relations, Vince Heald of Beck Ellman Heald,+1-858-453-9600, vheald@behmedia.com, for Bridgetech HoldingsInternational, Inc.; or Investor Relations, Redwood Consultants, LLC,+1-415-884-0348, for Bridgetech Holdings International, Inc.
Web site: http://www.bthi.com//
